The antibiotics market is expected to reach USD 57.0 billion
by 2024, according to the new report by Grand View Research, Inc. Rising
prevalence of infectious diseases especially in developing regions such as Asia
Pacific and MEA is anticipated to contribute towards market growth.
More than 15.0% of the deaths, in children below the age of five, are
estimated to be due to pneumonia and according to the statistics provided by
the WHO about 9.2 million deaths were recorded in 2015. Similar to
tuberculosis, the highest prevalence of the disease is identified to be in the
South Asian and Sub-Saharan regions. Currently, the required antibiotic
treatment is available only to one third of the infected population, thereby
increasing the disease burden.
Government reforms specific to antibiotics such as the Generating
Antibiotics Incentives Now (GAIN) Act in the U.S. are projected to help market
growth over the forecast period. This further expected facilitate development
of advanced drugs.
On the contrary, uncertain regulatory policies are likely to hinder the
growth of this vertical impacting market growth significantly. In 2013, the
U.S. FDA revised the guidance for registration trials for drugs used in the
treatment of acute bacterial skin and skin structure infections. The guidance
states the use of short term measures of anti-infective efficacy (percent
reduction in lesion size at 48 to 72 hours) as opposed to long term measures
such as resolution of infection at 10-14 days, which is termed as Test to Cure
or TOC.
Full research report on antibiotics market analysis: http://www.grandviewresearch.com/industry-analysis/antibiotic-market
Further Key Findings From the Study Suggest:
·
Antibiotic segment including tetracyclines,
imidazoles, lincosamides and monoclonal antibodies held commanding share in
2015 and are also anticipated to grow at a lucrative growth rate over the
forecast period
·
Development of monoclonal antibodies for
antibiotic resistant microorganism is key highlight of this segment. Increasing
incidences of pneumonia, blood stream infections, and urinary tract infections
(UTI) are anticipated to foster the usage of carbapenems class of antibiotics.
·
Cell wall synthesis inhibitors dominated
the mechanism outlook in 2015. Majority of the antibiotics such as penicillins,
cephalosporins and carbapenems forms the cell wall synthesis inhibitor class.
·
RNA synthesis inhibitors as well as folic
acid synthesis inhibitors are anticipated to witness healthy growth over the
forecast period. Development of several antiviral drugs which inhibit
transcription and reverse transcription process are anticipated to support the
growth. Folic acid inhibitor sulfa drugs are anticipated to grow as they have
wide application scope.
·
Asia Pacific on account of huge population
base, high prevalence of infectious diseases, regulation reforms and greater
usage of generic medicine held commanding share in 2015.
·
Latin America, especially Brazil with
strong growth in pharmaceutical sector is also projected to exhibit
remunerative growth. Outbreak of certain viruses such as Ebola in African
region also contributed towards the significant growth of MEA region.
·
Some of the key players in this vertical
are Pfizer, Inc., Janssen Pharmaceuticals, Abbott, GlaxoSmithKline plc, Sanofi,
Novartis AG, Bayer AG, Bristol Myers Squibb Company, Eli Lilly and Company and
Astellas Pharma, Inc.
View more reports of this category by Grand View Research
at: https://www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the antibiotics market on the basis of
drug class and region:
Global Antibiotics
Drug Class Outlook (Revenue, USD Million, 2013 - 2024)
·
Cephalosporins
·
Penicillins
·
Fluoroquinolones
·
Macrolides
·
Carbapenems
·
Aminoglycosides
·
Sulfonamides
·
Other
Global Mechanism
Outlook (Revenue, USD Million, 2013 - 2024)
·
Cell Wall Synthesis Inhibitors
·
Protein Synthesis Inhibitors
·
DNA Synthesis Inhibitors
·
RNA Synthesis Inhibitors
·
Mycolic Acid Inhibitors
Antibiotics
Regional Outlook (Revenue, USD Million, 2013 - 2024)
·
North America
o U.S.
o Canada
·
Europe
o UK
o Germany
·
Asia Pacific
o Japan
o China
o India
·
Latin America
o Brazil
o Mexico
·
MEA
o South Africa
Access Full Press Release of this
Report:
https://www.grandviewresearch.com/press-release/global-antibiotic-market
https://www.grandviewresearch.com/press-release/global-antibiotic-market
About Grand View Research
Grand View
Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, we offer
market intelligence studies ensuring relevant and fact-based research across a
range of industries, from technology to chemicals, materials and healthcare.
For more information: https://www.grandviewresearch.com/
